Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 17/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | FGFR1 | P11362 | 9/20 | 0.53 |
| ▸ | FGFR2 | P21802 | 5/20 | 0.53 |
| ▸ | FGFR3 | P22607 | 5/20 | 0.53 |
| ▸ | RPS6KB2 | Q9UBS0 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CSF1R | P07333 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29385382 | 1.00 | FGFR4 (0.69) | FGFR4KDM4EALDH1A1SMN1; SMN2FGFR1 | |
| SCHEMBL21154002 | 0.92 | FGFR4 (0.60) | FGFR4KDM4EALDH1A1SMN1; SMN2FGFR1 | |
| SCHEMBL21154059 | 0.90 | FGFR4 (0.56) | FGFR4KDM4EALDH1A1SMN1; SMN2FGFR1 | |
| SCHEMBL16683513 | 0.87 | FGFR4 (0.67) | FGFR4FGFR1FGFR2FGFR3RPS6KB2 | |
| SCHEMBL16676911 | 0.86 | FGFR4 (0.66) | FGFR4FGFR1FGFR2FGFR3RPS6KB2 | |
| SCHEMBL16674626 | 0.84 | FGFR4 (0.63) | FGFR4FGFR1FGFR2FGFR3RPS6KB2 | |
| SCHEMBL28495534 | 0.83 | FGFR4 (0.62) | FGFR4FGFR1FGFR2FGFR3RPS6KB2 | |
| SCHEMBL27746938 | 0.82 | KDM4E (0.64) | FGFR4KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL21153635 | 0.82 | FGFR4 (1.00) | FGFR4FGFR1FGFR2FGFR3RPS6KB2 | |
| SCHEMBL21153921 | 0.81 | FGFR4 (0.60) | FGFR4FGFR1FGFR2FGFR3RPS6KB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114057700-B | Crystal forms of fibroblast growth factor receptor inhibitor and preparation method thereof | 药捷安康(南京)科技股份有限公司 | 2024-04-19 | — | — | CN | disclosed |
| US-20240043408-A1 | CRYSTAL FORM OF FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITOR AND PREPARATION METHOD THEREFOR | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2024-02-08 | — | — | US | disclosed |
| CN-117510513-A | Heterocyclic compounds having biological activity | 首药控股(北京)股份有限公司 | 2024-02-06 | — | — | CN | disclosed |
| WO-2024022244-A1 | HETEROCYCLIC COMPOUND HAVING BIOLOGICAL ACTIVITY | 首药控股(北京)股份有限公司 | 2024-02-01 | — | — | WO | disclosed |
| EP-4190775-A1 | CRYSTAL FORM OF FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITOR AND PREPARATION METHOD THEREFOR | Transthera Sciences (Nanjing), Inc. (CN) | 2023-06-07 | — | — | EP | disclosed |
| EP-3395814-B1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORP (US) | 2022-04-06 | — | — | EP | disclosed |
| EP-3395814-B1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORP (US) | 2022-04-06 | — | — | EP | disclosed |
| CN-114057700-A | Crystal form of fibroblast growth factor receptor inhibitor and preparation method thereof | 药捷安康(南京)科技股份有限公司 | 2022-02-18 | — | — | CN | disclosed |
| CN-110028491-B | Fibroblast growth factor receptor inhibitors | 缆图药品公司 | 2022-02-11 | — | — | CN | disclosed |
| US-20210347756-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORPORATION | 2021-11-11 | — | — | US | disclosed |
| US-8802697-B2 | Inhibitors of the fibroblast growth factor receptor | BLUEPRINT MEDICINES CORPORATION (US) | 2014-08-12 | — | — | US | disclosed |
| US-8802697-B2 | Inhibitors of the fibroblast growth factor receptor | BLUEPRINT MEDICINES CORPORATION (US) | 2014-08-12 | — | — | US | disclosed |
| US-8802697-B2 | Inhibitors of the fibroblast growth factor receptor | BLUEPRINT MEDICINES CORPORATION (US) | 2014-08-12 | — | — | US | disclosed |
| US-20140187559-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORPORATION (US) | 2014-07-03 | — | — | US | disclosed |
| US-20140187559-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORPORATION (US) | 2014-07-03 | — | — | US | disclosed |
| US-20140187559-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORPORATION (US) | 2014-07-03 | — | — | US | disclosed |
| US-20140088100-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES (US) | 2014-03-27 | — | — | US | disclosed |
| US-20140088100-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES (US) | 2014-03-27 | — | — | US | disclosed |
| WO-2014011900-A2 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES (US) | 2014-01-16 | — | — | WO | disclosed |
| WO-2014011900-A2 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES (US) | 2014-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210347756-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | FGFR4, FGFR1, FGFR2 | FGFR4 1/4885KDM4E 976/4885ALDH1A1 1963/4885 |
| US-20140088100-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | FGFR1, FGFR2, FGFR3 | FGFR4 5/4885KDM4E 2039/4885ALDH1A1 2544/4885 |
| US-20240043408-A1 | CRYSTAL FORM OF FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITOR AND PREPARATION METHOD THEREFOR | FGF2, FGFR1, FGF1 | FGFR4 8/4885KDM4E 4444/4885ALDH1A1 1880/4885 |
| US-20140187559-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | FGFR1, FGFR2, FGFR3 | FGFR4 5/4885KDM4E 2039/4885ALDH1A1 2544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.